Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: May 20, 2011

Premium

Vermillion this week appointed Bruce Huebner to its board of directors.

Currently Huebner is managing director at the healthcare consulting firm LynxCom Partners. Previously he was president and CEO of microarray company Nanogen, and before that he was executive vice president and chief operating officer of Gen-Probe.


Stacey Sias has left her positions at Celera as senior VP of business development and strategic planning and as an executive director, the company said in a recent filing with the US Securities and Exchange Commission.

Sias previously was VP of licensing at Roche Molecular Systems, she was a molecular biologist at Codon and Genentech, and she is a registered patent agent with the US Patent and Trademark Office.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.